Clinical trials: Non-Hodgkins Lymphoma
Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
The purpose of this trial is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of GEN3017 as a monotherapy in participants with relapsed or refractory…
- Trial name
- NCT06018129
- Testing
- GEN3017
- Where
- 4 sites in United States, Australia
- Volunteers
- 9 people
- Sponsor
- Genmab
Chronic Myeloproliferative Disorders, Leukemia
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
RATIONALE: Questionnaires that measure quality-of-life may improve the health care team's ability to plan supportive care for patients undergoing donor bone marrow transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281801
- Testing
- psychosocial assessment and care, Quality of Life Assessments
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Case Comprehensive Cancer Center
Non-Hodgkin's Lymphoma
Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma
The main purpose of this study is to determine the effects (good and bad) and the safety of Dynavax's immunostimulatory phosphorothiolate oligodeoxyribonucleotide (1018 ISS) given in combination with Rituxan on patients with…
- Trial name
- NCT00251394
- Testing
- Rituxan, 1018 ISS
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TC-110 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human CD19, fused to the CD3-epsilon subunit which, upon expression, is…
- Conditions
- Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT04323657
- Testing
- TC-110 T Cells, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- TCR2 Therapeutics
Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
While chimeric antigen receptor T-cell (CAR T-cell) therapy produces impressive response rates in heavily pre-treated patients, early loss of response remains a barrier.
- Trial name
- NCT05044039
- Testing
- Duvelisib, CAR T-cells
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
CD20 Positive B Cell NHL
Pharmacokinetics, Efficacy and Safety of the 304 Injection
The purpose of this study is to evaluate the pharmacokinetic of the experimental drug 304 injection compared with rituximab injection in patients with CD20 positive B-cell non-Hodgkin lymphoma who had previously achieved CR/CRu…
- Trial name
- NCT03980379
- Testing
- 304 injection, rituximab injection
- Where
- 10 sites in China
- Volunteers
- 60 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
This phase Ib/II trial investigates the side effects of mogamulizumab and extracorporeal photopheresis and to see how well they work in treating patients with Sezary syndrome or mycosis fungoides.
- Conditions
- Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome
- Trial name
- NCT04676087
- Testing
- Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
This pilot clinical trial studies low-dose total body irradiation and donor peripheral blood stem cell transplant followed by donor lymphocyte infusion in treatment patients with non-Hodgkin lymphoma, chronic lymphocytic…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT00003196
- Testing
- chemotherapy, total-body irradiation, peripheral blood stem cell transplantation
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 63 people
- Sponsor
- Fred Hutchinson Cancer Center
Follicular Lymphoma, Small Lymphocytic Lymphoma
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
The primary objective will be to assess the overall response rate and to evaluate the efficacy and safety of idelalisib (IDELA; GS-1101) in participants with previously treated indolent Non-Hodgkin Lymphoma (iNHL) that is…
- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- DELTA (NCT01282424)
- Testing
- Idelalisib
- Where
- 41 sites in United States, France and 4 more
- Volunteers
- 125 people
- Sponsor
- Gilead Sciences
Non-Hodgkin's Lymphoma, Lymphoma
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
Primary Objective: Evaluate the effect of zoledronate on change in bone mineral density (BMD) at the total lumbar spine and femoral neck.
- Trial name
- NCT00352846
- Testing
- Zoledronic Acid, Vitamin D, Calcium Carbonate
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
PTCy and ATG for MSD and MUD Transplants
Hematopoietic stem cell transplantation is a curative treatment for a number of benign and malignant hematologic diseases. One of the key parts of hematopoietic stem cell transplantation is the prophylaxis of graft-versus-host…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Hodgkin Lymphoma
- Trial name
- NCT06299462
- Testing
- ATG 5.0, Cyclophosphamide injection, ATG 4.0
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Anaplastic Large Cell Lymphoma
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
This phase II trial studies how well alisertib works in treating patients with peripheral T-cell non-Hodgkin lymphoma that has come back after a period of improvement or has not responded to treatment.
- Conditions
- Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma
- Trial name
- NCT01466881
- Testing
- Alisertib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 161 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, B-Cell, Autologous Stem Cell Transplantation
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
The study is designed to evaluate the efficacy and safety of chimeric antigen receptor T-cell therapy following autologous stem cell transplantation for relapsed/refractory B-cell Non-Hodgkin's lymphoma.
- Trial name
- NCT06381830
- Testing
- Apheresis, Autologous Stem Cell Transplantation, CAR-T Cell Therapy
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Non Hodgkin's Lymphoma, NHL
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
The goal of this study is to evaluate a new approach to immunotherapy in NHL by combining two antibodies, veltuzumab and epratuzumab.
- Conditions
- Non Hodgkin's Lymphoma, NHL, Aggressive NHL, Diffuse Large B-cell Lymphoma
- Trial name
- NCT01101581
- Testing
- Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab tetraxetan, veltuzumab
- Where
- 7 sites in United States
- Sponsor
- Gilead Sciences
Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as initial salvage therapy in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or…
- Conditions
- Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT04665765
- Testing
- Carboplatin, Etoposide, Ifosfamide
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- City of Hope Medical Center
Lymphoma, NHL
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877
This study has two parts (A and B). The primary purpose of Part A is to find the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a twice…
- Conditions
- Lymphoma, NHL, Non-Hodgkin Lymphoma
- Trial name
- NCT00471367
- Testing
- AZD4877
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Lymphoma
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228
This is the first-in-human study with BYON4228, a humanized monoclonal antibody (mAb) directed against SIRPα.
- Trial name
- NCT05737628
- Testing
- BYON4228 + Rituximab
- Where
- 12 sites in Italy, Netherlands and 2 more
- Volunteers
- 17 people
- Sponsor
- Byondis B.V.
Lymphoma
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002565
- Testing
- bleomycin sulfate, CHOP regimen, cisplatin
- Where
- 3 sites in United States, Brazil and 1 more
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of thalidomide in treating patients who have relapsed or refractory low-grade non-Hodgkin's lymphoma.
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma
- Trial name
- NCT00022581
- Testing
- thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of flavopiridol in treating children who have relapsed or refractory solid…
- Conditions
- Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma
- Trial name
- NCT00012181
- Testing
- alvocidib, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)